Quoin Pharmaceuticals

QNRX Rare disease Lead: Phase 2 ★ Read the deep dive → 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-26

Catalyst timeline

QRX003 Ph2 readout2H 2026QRX003 Ph2 readout, 2H 2026, notable
QRX003 Ph3 start2H 2026QRX003 Ph3 start, 2H 2026, notable
QRX003 PSS Ph2 start2H 2026QRX003 PSS Ph2 start, 2H 2026, notable
QRX009 IND filing3Q 2026QRX009 IND filing, 3Q 2026, notable
QRX003 NDA filing2027QRX003 NDA filing, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

QYLEKI

QRX003

Small Molecule Target: kallikreins, serine protease

Netherton Syndrome Phase 2 topical Skinvisible NCT05521438
Peeling Skin Syndrome Phase 2 Phase 2/3 trial topical Skinvisible

QRX008

Small Molecule Target: VLA-4

Scleroderma Preclinical Queensland University of Technology

rapamycin

sirolimus · QRX009

Small Molecule Target: mTOR

Undisclosed indication Preclinical topical University College Cork

Discontinued (1)

QRX007 — Netherton Syndrome · discontinued in July 2025 in light of expected near-term completion of QRX003 clinical program for NS

Biotech Distilled coverage (2)

2026-08-15 UPDATE: Quoin Pharmaceuticals (QNRX) - The Clock Runs Faster Than the Catalysts 🔒 Paid
2026-06-25 Quoin Pharmaceuticals (QNRX) — Scientific Deep Dive for QRX003 (QYLEKI) and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.